415 Capital
InvestorActive415 Capital Management GmbH is a Munich-based specialist venture capital firm exclusively focused on breakthrough medical technology. The firm invests in clinical- through commercial-stage MedTech companies addressing large unmet patient needs in chronic diseases, with a primary emphasis on cardiovascular and neurovascular disorders. It also selectively backs neuromodulation, medical robotics, and technologies at the intersection of patient monitoring, medical imaging, and AI. Geographic focus spans Europe, Israel, and North America. Initial check sizes range from €5M to €15M per company. Founded in 2018, the team draws on over 30 years of MedTech investing experience. The firm's first institutional fund targeted €85M (closed 2020); its second fund, 415 Capital Fund II, was announced in October 2024 with a €150M target and anticipated final close by end of Q1 2025. As of the Fund II announcement, the firm managed nearly $200M in assets. Portfolio companies have attracted over €600M in follow-on financing.
Founder Intel
Sign in to read intel from founders who have worked with 415 Capital.
What founders say about 415 Capital
Be the first to share intel on 415 Capital — it's free.
Get Started FreeRelated on The List
- Seattle Angel Conference — Investor · N America
- Ideaship — Investor · N America
- ADVentures — Investor · Wilmington, MA, United States
- Align Ventures — Investor · Miami, FL, United States
- Angelini Ventures — Investor · Rome, Italy
Comparing options? Founders discuss fundraising in the forum, or browse the rest of The List.